[서울=뉴스핌] Reporter Bang Bo-kyung = GC Green Cross announced on the 1st that it has received final approval from the Indonesian Ministry of Health and Welfare for business rights related to the construction and transfer technology of blood product plants.
The Indonesian government went on to select a business operator with the right to build a blood product plant and transfusion technology, and in January, selected GC Green Cross as the preferred bidder. After detailed discussions and coordination, the company was officially notified of business approval.
GC Green Cross is the only company that has successfully completed the export of blood product plants worldwide. Not only was it the first domestic pharmaceutical company to export a blood product plant to Thailand, but it also has experience and knowledge in building factories in different countries such as China and Canada.
The Indonesian government intends to realize a stable localization of blood products by producing blood products, which currently depends entirely on imports, with the plasma of Indonesian citizens through the blood product plant construction and technology transfer project.
The company said, “With the approval of this license, GC Green Cross’ high technology in the field of blood derivatives for half a century has been recognized globally once again.”